Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biorestorative Therapies Inc (NQ: BRTX )

1.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biorestorative Therapies Inc

< Previous 1 2 3 4 5 Next >
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
By Faith Ashmore, Benzinga 
Via News Direct
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.  
Via Benzinga
See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!
While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in... 
Via Benzinga
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
By David Willey, Benzinga 
Via News Direct
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via Benzinga
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
By Paul Henley, Benzinga 
Via News Direct
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. 
Via Benzinga
EXCLUSIVE: BioRestorative Therapies Adds Additional Sites For Lumbar Disc Disease Trial
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into agreements with Vantage Clinical Trials LLC for its Phase 2 trial targeting chronic lumbar disc disease (cLDD).  
Via Benzinga
Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders
In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy weight. 
Via Benzinga
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
BioRestorative Shares Fall As Enrolment Initiated in Mid-Stage Chronic Back Pain Drug Study
BioRestorative Therapies (NASDAQ: BRTX) enrolled first patient in the phase 2 clinical study of its lead drug BRTX-100 in chronic lumbar disc disease (cLDD). 
Via Benzinga
EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study
BioRestorative Therapies Inc (NASDAQ: BRTX) has selected the Center for Clinical Research in North Carolina as the company's second contract for its Phase 2 trial targeting chronic lumbar disc disease... 
Via Benzinga
4 Stocks Under $4 Insiders Are Aggressively Buying
The Nasdaq Composite jumped around 390 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pharming (NASDAQ:PHAR) shares increased by 15.8% to $10.21 during Wednesday's pre-market session. The company's market cap stands at $652.2 million.... 
Via Benzinga
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of... 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K... 
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb
US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Absci (NASDAQ:ABSI) shares increased by 51.5% to $9.3 during Friday's pre-market session. The market value of their outstanding shares is at $861.1 million.... 
Via Benzinga
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 27.89% to $1.88 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares surged 53.4% to settle at $16.31 on Wednesday. Acasti Pharma Inc. (NASDAQ: ACST) jumped 52.3% to close at $1.69 on... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.